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Analysis of Global Pediatric Cancer Research
and Publications
Eleni Syrimi, MD1; Grant Lewison, PhD2; Richard Sullivan, PhD2; and Pamela Kearns, PhD3
abstract
This study sought to investigate the amount of global research activity and investment in pediatric cancer
research, using publications as a proxy measure, and to understand geographical differences in research
activity. To do this, we used a quantitative method—bibliometrics—to analyze Web of Science publications in
the 10 years from 2007 to 2016. We found that global pediatric cancer research outputs have increased from
2,937 in 2007 to 4,513 in 2016, at an annual growth rate of 4.3%. This rate is slower than for both cancer
research as a whole and general pediatric research. The increase in output was due almost entirely to China.
International collaboration was similar to that in cancer research overall, with the highest levels among countries
in close geographical proximity. Hematological and CNS childhood cancers are the main areas for research.
Genetics and prognosis were the main research domains, and there was little work on radiotherapy or palliative
care. In terms of citations, the best-performing countries were the Netherlands, the United States, and the
United Kingdom. On the basis of estimates of the cost of research papers in different countries, the total world
pediatric cancer research expenditure is estimated to have been 1.54 billion US dollars (USD) in 2013, and 1.79
billion USD in 2016. Our data suggest that current global policy toward pediatric cancer needs significant review
and change to increase investments, balance research portfolios, and improve research that is relevant to low-
and middle-income countries.
JCO Global Oncol 6:9-18 © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Despite the overall improvement in outcomes for most
childhood malignancies in high-income settings, cure
remains challenging for some diseases, such as bone
sarcomas and certain types of brain tumors.1 Cancer
remains the leading cause of death in children , 15
years old in Western Europe.2 Long-term personal
and socioeconomic impacts of treatment still remain
substantial, with 20%-40% of childhood cancer sur-
vivors suffering major long-term disability due to the
disease and/or treatment.3 In low-income and middle-
income countries, chronic infections outweigh cancer
deaths in all age groups.4 Given the youth bulge in
these countries,5 there are more cases of childhood
cancer than in high-income countries. Survival re-
mains poor because of inadequate treatment or lack of
treatment.6
Table 1 shows the distribution of the burden
(disability-adjusted life years [DALYs], taking into
account both early death and years lived with
a disability) in 4 groups of countries, classified by
income level (high, upper-middle, lower-middle, and
low) in 2000 and 2015.7 The burden has decreased in
upper-middle and high-income countries. However, in
low and lower-middle–income countries, the burden has
increased.
The importance of research as a major driver for better
outcomes has been well recognized and validated.8
However, there has been a paucity of strategic in-
telligence and a tendency to neglect global pediatric
cancer research,9 making it difficult for policymakers
to devise evidence-based strategies. Notably, a 2011
study showed that pediatric cancer accounted for only
just over 5% of all cancer research.10 Other minor
studies examining citations of pediatric cancer
papers11 and a specific examination of German
outputs12 added little additional useful data to inform
national and international research policies and re-
flected an overall lack of high-quality intelligence on
global pediatric cancer research.
In light of the need for an up-to-date and deeper
understanding of the state of global research into
pediatric cancer, we have used bibliometric
methods13 to describe the current research activity in
this area, particularly changes in the patterns of
outputs, the extent of international collaboration, and
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estimates of global expenditure on pediatric cancer
research.
METHODS
Selection of Papers
Articles and reviews were selected from the Web of Science
(WoS) for the 10 years, 2007-2016, that were identified by
both an existing pediatrics filter and a cancer filter. These
filters each consisted of lists of specialist journals and title
words. They were developed interactively by a bibliome-
trician (G.L.) and a specialist in the subject area, and their
precision (specificity) and recall (sensitivity) were de-
termined by E.S., who marked sets of papers as relevant or
not.14 The specificity was 0.82 6 0.024, based on the
means of 6 samples of 200 papers. The sensitivity was
0.75, so the filter’s calibration factor (by which the apparent
total must be multiplied to give the true” total) was 0.82/
0.75 = 1.09.
The bibliographic details of the papers were downloaded,
500 at a time, to a series of text files and then converted to
an Excel spreadsheet by means of a visual basic program
(macro) written by Philip Roe of Evaluametrics (Saint
Albans, United Kingdom). The countries were determined
for each paper as fractional counts. For example, a paper
with two French addresses and one German one would be
classed as FR 0.67, DE 0.33. We focused attention on the
leading 16 countries (Table 2).
International Collaboration
An overall measure compares the sum of the contributions
of individual countries with the world total, which is ef-
fectively the sum of the individual country fractional counts,
although there are a few papers without addresses. A
second measure compares each international pairing with
the numbers of coauthored papers that might have been
expected if country A chose its partners equally among
other countries on the basis of their fractional presence
within the field. For example, the foreign contribution to the
2,846 papers with a German author was 902 papers, and
of these, Austrian authors contributed 55.5, or 6.15%,
whereas their contribution to the field was 246.5 papers on
CONTEXT
Key Objective
What is the state of the global research in the pediatric oncology field?
Knowledge Generated
Pediatric cancer research output has been static over the last decade, with a lack of international collaborations. There is
a need internationally for greater investment in the field, with increased focus on low- and middle-income settings, where
the burden (measured in disability-adjusted life years) from pediatric cancer is much higher.
Relevance
Collectively, research and development funds should take these findings into consideration and coordinate initiatives that
enhance research and investment in the pediatric cancer field.
TABLE 1. Pediatric Cancer Data in 2000 and 2015 for Age Groups 0 to 15 Years
Income
2000 2015
Pediatric Cancer DALYs per caput % of DALYs Pediatric Cancer DALYs per caput % of DALYs
High 750 0.31 2.71 622 0.26 2.97
Ratio 0.83 0.85 1.10
Upper-medium 3,826 0.66 2.25 2,378 0.48 2.49
Ratio 0.62 0.73 1.10
Lower-medium 3,012 0.37 0.45 3,317 0.37 0.77
Ratio 1.10 1.00 1.70
Low 810 0.43 0.28 1,191 0.44 0.58
Ratio 1.47 1.03 2.09
World 8,398 0.46 0.73 7,508 0.39 1.00
Ratio 0.89 0.86 1.37
NOTE. WHO data for pediatric cancer burden for countries in four income groups (high, upper-medium, lower-medium, low) in 2000 and
2015, DALYs for pediatric cancer, DALYs per caput, and pediatric cancer DALYs as % of all causes, for age groups 0 to 15 years.
Abbreviation: DALY, disability-adjusted life year.
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a fractional count basis, or 0.65%. So, their contribution to
German papers was more than 9 times what might have
been expected (5.9 papers).
Delineation of Subject Areas
Subfilters were developed by R.S. and G.L., with assistance
from Ajay Aggarwal of King’s College London, to identify
papers in 10 different research domains and those relevant
to 10 individual anatomic cancer sites (Table 3). These also
consisted of lists of title words and journal name strings.
These subfilters were applied to the pediatric cancer file,
and each paper was marked with its research domain(s)
and cancer site(s). Some papers could not be classified,
and some were classified into more than one domain or
site. We also classified the papers by their research level
(R.L.) as clinical, basic, or both, on the basis of words in
their titles.15
Citation Measures
The traditional citation measure for a group of papers is the
arithmetic mean of the count of citations in a given time
window. This is essential so that all papers are evaluated
fairly. We have used a 5-year citation window beginning in
the year of publication so as to include the peak year for
almost all papers. However, this means our analysis was
restricted to the years 2007-2012.
The arithmetic mean of citation counts suffers from bias
caused by a few papers having an enormous number of
citations, and it has been suggested16 that the geometric
mean gives a fairer estimate. We augmented the cita-
tion counts by unity, then took logarithms of these en-
hanced counts, weighted them according to each country’s
TABLE 2. List of 18 Leading Countries in Pediatric Cancer Research
With Their ISO2 Codes
Country ISO2 Country ISO2 Country ISO2
Australia AU India IN Spain ES
Brazil BR Italy IT Sweden SE
Canada CA Japan JP Taiwan TW
China CN Netherlands NL Turkey TR
France FR Poland PL United Kingdom UK
Germany DE South Korea KR United States US
Abbreviation: ISO2, International Organization for Standardization
alpha 2 country codes.
TABLE 3. List of Pediatric Cancer Anatomic Sites and Research Domains, With Codes
ICCC-3 Code Site Code
I Leukemias, myeloproliferative diseases, and myelodysplastic diseases LEU
II Lymphomas and reticuloendothelial neoplasms LYM
III CNS and miscellaneous intracranial and intraspinal neoplasms CNS
IV Neuroblastoma and other peripheral nervous cell tumors PNS
V Retinoblastoma EYE
VI Renal tumors KID
VII Hepatic tumors LIV
VIII Malignant bone tumors BON
IX Soft tissue and other extraosseous sarcomas SAR
X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads GER
XI Other malignant epithelial neoplasms and malignant melanomas OTHER
Research Domain
Chemotherapy CHEM
Diagnosis DIAG
Epidemiology EPID
Genetics GENE
Palliative and supportive care PASU
Pathology PATH
Prognosis PROG
Survival SURV
Radiotherapy RADI
Screening SCRE
Surgery SURG
Targeted therapy TARG
Abbreviation: ICCC-3, International Classification of Childhood Cancer (ed 3).
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fractional presence on each paper, and then divided the
sum of these products by the fractional sum of the country’s
citable papers. The resulting quotient was then used as the
power of 10 and unity subtracted to give the geometric
mean. This was usually approximately half the arithmetic
mean.
A third measure of citation performance is the percentage
of a country’s papers that are cited highly enough to put
them in the top 5% of the total field, or some other per-
centile. The ratio of this percentage to the nominal per-
centile, multiplied by 100, is designated the WorldScale
value, by analogy with oil tanker charter rates.17 For ex-
ample, Germany published 1,171 citable papers, and 78 of
them received enough citations to put them in the top
5%, so its WorldScale value was 100 × 78/(1,171 ×
0.05) = 131.
The Funding of Pediatric Cancer Research
We estimated this by multiplying the estimated cost of
a paper in different countries (as a function of income per
caput; Data Supplement) by the fractional counts of papers
from each country and then summing the products (see
Data Supplement for more methodology details.) This gives
a more complete tally of expenditures than inquiries of
individual funders would do, as there are very large
numbers of these, and they may also use different defi-
nitions of the subject area and different currencies.
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FIG 1. Graph showing outputs of pediatric cancer research papers in the Web of Science (WoS) for 3 groups of
countries, 2007-2016. CA, Canada; EUR31, European Economic Area 31; RoW, rest of the world; US, United States.
–50
0
50
100
150
200
250
300
CN JP DE IT UK CA FR TR IN NL KR AU BR ES SE PL TW
Mean
AAPG x 10
Pa
pe
rs
 p
er
 y
ea
r a
nd
 A
AP
G 
x 
10
FIG 2. Outputs of pediatric oncology papers per year, 2007-2016, from 17 leading countries, and Annual Average
Percentage Growth (AAPG, × 10). AU, Australia; BR, Brazil; CA, Canada; CN, China; DE, Germany; ES, Spain; FR,
France; IT, Italy; IN, India; ISO, International Organization for Standardization country codes; JP, Japan; KR, South Korea;
NL, Netherlands; PL, Poland; SE, Sweden; TR, Turkey; TW, Taiwan; UK, United Kingdom; US, United States.
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RESULTS
Outputs of the World and of Individual Countries
Figure 1 shows the growth of pediatric cancer research over
the 10-year study period 2007-2016 and its division among
3 groups of countries. On average, pediatric cancer re-
search represented 4.7% of all cancer research in 2007-
2016. Overall, the number of pediatric cancer research
papers increased from 2,937 papers in 2007 to 4,513 in
2016, or by 4.3% per annum (p.a.), but was slower than the
growth in cancer research overall or in pediatrics. The
proportions of pediatric cancer research within cancer
research and pediatrics went down from 5.1% to 4.3% and
from 7.8% to 7.2%, respectively.
The papers were published in 2,831 different journals, but
two were used relatively frequently: Pediatric Blood &
Cancer (3,823 papers, 10.0%) and Journal of Pediatric
Hematology Oncology (2,100 papers, 5.5%). It was notable
that the increase in output from the rest of the world (RoW;
Fig 1) is due almost entirely to China, where output grew at
27% p.a. No other country in the top 18 (Data Supplement)
exceeded 7% p.a. growth (Fig 2). For two countries, Ger-
many and the United Kingdom, growth was actually
negative in this time period. A comparison of country outputs
in 2012-2016 with gross domestic product (GDP) is shown
in the Data Supplement. The United States and Turkey are
clearly outperforming the other countries by a factor of 2. On
the other hand, Brazil and Spain are publishing only ap-
proximately half of what might have been predicted.
International Collaboration
There were 38,193 pediatric cancer papers published in
2007-2016, and the sum of the individual country counts
was 49,972, or 1.31 times the number of papers. In the
same years it was 1.25 for pediatrics research in 2007,
increasing to 1.38 in 2016. The corresponding figures for
cancer research were 1.24 and 1.35. This shows that the
level of international collaboration in pediatric cancer re-
search was similar to that in other fields.
Another measure of international collaboration, based on
a country’s choice of individual partners, is shown in
Figure 3. For many countries, most of the cells show a ratio
, 0.05, indicating that they do not favor other countries in
this set; this applies in particular to the Asian countries, but
there are some exceptions, such as Taiwan’s preference for
work with South Korea (data not shown). On the other hand,
ISO US CN JP DE IT UK CA FR TR IN NL KR AU BR ES SE
1.6SE 0.54 0.29 0.14 1.65 0.89 1.6 0.47 0.94 0.1 0.07 2.59 0.02 1.01 0.09
ES 0.73 0.14 0.08 1.87 1.75 2.76 0.3 2.57 0.14 0 1.49 0.05 0.49 1.63 2.64
0.49BR 1.14 0.03 0.06 1.27 0.61 1.66 2.44 2.26 0.11 0.13 1.62 0.01 1.16 2.16
AU 1.39 0.51 0.1 0.95 0.47 2.54 1.31 1.31 0.03 0.64 1.2 0.09 0.66 0.33 0.84
0.63KR 1.76 0.53 1.06 0.56 0.46 0.48 0.71 0.29 0.23 0.36 0.21 2.72 0.04 0.42
NL 0.53 0.07 0.19 3.04 1.26 2.71 0.73 1.82 0.21 0.09 0.04 1.21 0.4 0.92 2.55
0.940.09IN 1.02 0.32 1.03 0.81 0.38 2.38 1.91 0.65 0.24 0.59 0.58 3.94 0.39
TR 0.96 0.22 0.37 1.25 1.06 1.22 0.5 1.11 0.28 2.2 0.36 0.51 0.48 0.94 1.55
FR 0.58 0.1 0.23 1.89 1.94 2.69 0.91 0.14 0.28 2.6 0.06 1.56 1 1.79 1.25
CA 1.83 0.23 0.11 0.65 0.63 1.08 0.75 0.08 0.24 0.8 0.23 1.23 1.06 0.14 0.52
UK 0.72 0.25 0.16 1.8 1.69 1.43 2.4 0.11 0.31 2.64 0.11 1.82 0.41 1.41 2.73
IT 0.78 0.09 0.17 2 2.23 0.72 2.44 0.19 0.08 2.15 0.15 1.01 0.52 1.98 1.15
DE 0.58 0.19 0.27 1.53 2.02 0.9 1.79 0.22 0.19 3.72 0.12 1.11 1.04 1.32 1.54
JP 1.11 0.66 1.58 0.81 1.22 0.97 1.54 0.3 0.42 0.88 0.68 1.05 0.07 0.33 1.56
CN 1.69 1.02 0.77 0.3 0.78 1.15 0.38 0.08 0.12 0.62 0.54 1.54 0.19 0.35 2.05
US 0.88 0.45 1.12 1.28 1.24 2.23 0.73 0.21 0.34 1.16 0.61 1.68 1 0.78 1.37
FIG 3. International collaboration expressed as 16 target countries’ (in left column) preference for partnering with
other countries (in top row), being the ratio of the observed fractional counts of coauthored papers compared with
the counts estimated if they were selected proportionately to their presence in pediatric oncology research (in the
absence of papers from the target country). Cells with ratios. 2.0 tinted dark green; with ratios. 1.414 tinted pale
green; with ratios, 0.707 tinted orange; with ratios, 0.5 tinted purple. AU, Australia; BR, Brazil; CA, Canada; CN,
China; DE, Germany; ES, Spain; FR, France; IT, Italy; IN, India; ISO, International Organization for Standardization
country codes; JP, Japan; KR, South Korea; NL, Netherlands; SE, Sweden; TR, Turkey; UK, United Kingdom; US,
United States.
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most European countries prefer to publish with neighboring
countries, particularly Germany. Australia chooses partners
in India and South Korea much more than might have
been expected. However, not all these differences between
observed and expected numbers of papers are statistically
significant.
Research Outputs for Different Pediatric Cancers and
Research Domains
Our results demonstrate that pediatric cancer research
was focused on the cancers most prevalent among
children, namely, leukemia and CNS cancers (Fig 4).
This occurred across all 3 world regions. Examination of
the research domains shows that they again were
working on broadly similar areas of research (Fig 5). The
2 main treatment modalities in pediatric cancer (che-
motherapy and targeted therapy) accounted for 10% of
the papers.
A cross-tabulation of the amount of research on the leading
cancer types and the 10 research domains showed that the
predominant research domains differed between cancer
types. As might be expected, surgery is mainly researched
in the solid cancers. The ratios of observed to expected
totals (integer counts) are shown in the Data Supplement.
Another cross-tabulation of the relative commitment of the
leading countries and the 3 world regions to different re-
search domains is shown in the Data Supplement.
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FIG 4. Partition of pediatric oncology research papers by cancer type: from EUR31 countries, Canada, USA, and
from the Rest of the World. Percentages of regional totals. BON, malignant bone tumors; CA, Canada; EUR31,
European Economic Area 31; GER, germ cell tumors, trophoblastic tumors, and neoplasms of gonads; KID, renal
tumors; LEU, leukemias, myeloproliferative diseases, and myelodysplastic diseases; LIV, hepatic tumors; LYM,
lymphomas and reticuloendothelial neoplasms; PNS, neuroblastoma and other peripheral nervous cell tumors;
RoW, rest of the world; SAR, soft tissue and other extraosseous sarcomas; US, United States. (*) Refers to papers on
any other identifiable tumor type as per ICCC-3 Code XI. It also includes papers where the anatomical site is not
specified but the title makes clear that they are about pediatric cancer.
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FIG 5. Partition of pediatric oncology research papers by domain (type of research) for papers from European
Economic Area 31 (EUR31) countries, from Canada and the United States (CA + US), and from the Rest of the
World (RoW). CHEM, chemotherapy; DIAG, diagnosis; EPID, epidemiology; GENE, genetics; PASU, palliative and
supportive care; PATH, pathology; PROG, prognosis; RADI, radiotherapy; SCRE, screening; SURG, surgery; SURV,
survival; TARG, targeted therapy.
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Citations of Papers From Leading Countries and in
Different Subject Areas
There were 20,934 potentially citable pediatric cancer papers,
and the top 5.08%, or 1,063 papers, received at least 37
citations in the 5-year time window. The results are shown in
Figure 6 for the 16 leading countries and for the 3 world
regions on 3 different measures. There is a high correlation
between these indicators: between the arithmetic and geo-
metric means, r2 = 0.94; between the arithmetic mean and
the mean WorldScale value, r2 = 0.92; and between the
geometric mean and the WorldScale value, r2 = 0.78. The
ranking of the top countries is similar on all 3 indicators, which
gives confidence that this is reliable in terms of citation impact.
The Netherlands is the clear leader, followed by the United
States and the United Kingdom. Almost all (24 out of 27)
highly cited papers, with actual citation impact of more than
200 citations, were published in very high-impact journals,
with a mean 5-year diachronous citation score (potential ci-
tation impact [PCI]) of 154, such as the New England Journal
of Medicine (PCI = 219) and The Lancet (PCI = 181).
The Funding of Pediatric Cancer Research
Our estimate of the 2013 costs of a biomedical paper for
each country as a function of its wealth per caput is shown
in the Data Supplement. These costs, when multiplied by
the numbers of papers from each country that year on
a fractional count basis, give a pie chart for the global
distribution of expenditure (Fig 7). The number of papers
has been increased by 9% to account for the lack of recall
(0.75) compared with the precision (0.82).
ISO Cited 1% 2% 5% A mean G mean WS 1% WS 2% WS 5% WS mean
NL 514 10.0 20.3 49.4 16.5 9.77 192 192 189 191
US 6749 117 238 570 15.0 7.95 171 171 166 169
UK 1017 13.4 30.0 79.2 13.6 7.17 131 143 153 142
DE 1171 18.9 32.4 78.1 12.9 6.59 159 134 131 141
FR 835 8.6 15.5 39.9 10.4 5.00 101 90 94 95
AU 372 2.7 7.6 17.9 12.6 8.08 72 99 95 89
IT 1007 8.4 19.4 46.5 10.8 6.00 82 93 91 89
CA 850 7.3 15.1 31.8 11.4 6.76 85 86 74 82
SE 300 1.5 3.5 16.2 12.2 8.09 49 56 106 70
ES 335 1.6 5.2 13.1 8.92 4.63 47 75 77 66
CN 830 2.6 8.9 18.9 7.90 4.58 31 52 45 42
JP 1135 4.0 5.5 14.9 6.66 3.95 35 24 26 28
BR 387 0.9 0.9 3.7 5.85 3.62 22 11 19 17
IN 632 1.1 1.1 4.0 4.55 2.66 16 8 13 12
PL 244 0.1 0.6 2.4 4.89 2.79 2 13 19 11
TW 235 0.0 0.5 0.6 5.91 3.83 1 11 5 5
KR 468 0.1 0.3 1.9 5.84 3.70 2 3 8 4
TR 836 0.4 0.4 0.7 3.32 2.09 5 2 2 3
CA+US 7599 124 253 602 14.6 7.81 161 162 156 160
EUR31 6757 73.2 147 381 11.6 6.07 107 106 111 108
RoW 6578 14.8 31.3 79.5 6.10 3.46 22 23 24 23
Total 20934 212 432 1063 10.95 5.62 100 100 100 100
FIG 6. Citation performance of leading 16 countries and 3 world regions in pediatric cancer research, 2007-12,
based on their presence in the top centiles, and arithmetic (A) and geometric (G) means of 5-year citation counts.
Countries ranked by mean WorldScale score (WS mean). Cells with with ratios . 1.414 world means tinted green;
with ratios, 0.707 tinted orange; with ratios, 0.5 tinted purple. AU, Australia; BR, Brazil; CA, Canada; CN, China;
DE, Germany; ES, Spain; EUR31, European Economic Area 31; FR, France; IT, Italy; IN, India; ISO, International
Organization for Standardization country codes; JP, Japan; KR, South Korea; NL, Netherlands; RoW, rest of the
world; SE, Sweden; TR, Turkey; UK, United Kingdom; US, United States.
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From this analysis, the United States dominated the ex-
penditure even more than it dominated the research output
distribution, with nearly 48% of the world total of $1.54
billion in 2013. The next countries, Germany and Japan,
each spent just over 6% of the total. Collectively, Canada
and the United States spent more than half the total (53%),
followed by the EUR31 countries (32%) and the RoW far
behind at 15%. Three countries (Japan, Australia, and
South Korea) provided 11%, or 71% of the RoW total.
There has been an increase in costs in the United States
of approximately 2% per year in the last few years.18
When this increment was applied to the cost per paper
for each country and to the estimated numbers of papers
from each country extrapolated from their totals in 2016,
we obtained a total expenditure of $1.79 billion in that
year, of which the United States would have contributed
$822 million and Japan, the second country, $106
million.
DISCUSSION
Pediatric cancer research output over the last decade has
not kept pace with pediatric and cancer research overall
and remains at , 5% of all cancer research output. It is
notable that China has made a substantial contribution to
the world total, and, without this, global output would have
fallen even further. This is a significant issue for both the
research community and research funders. However, in the
context of national wealth, there appears to be a good-
correlation between research output and GDP for most
countries. On this metric, China’s research output becomes
proportionate, while the United States and Turkey are out-
performing compared with Brazil, which is underperforming
in relation to its GDP. This suggests that countries’ strategies
toward pediatric cancer research have becomemostly static.
Using publication coauthorship as a surrogate for in-
ternational collaboration, we saw little difference between
the level of collaborative research in pediatric cancer and all
types of cancer research. We also noted that there was
a tendency for countries to collaborate with those in close
geographical proximity. Within Europe, the United Kingdom
and the Netherlands were the countries whose research
outputs included the highest numbers of collaborators.
Given the rarity of pediatric cancers and the existence of
well-established international networks, we had expected
more collaboration. The data do not give any insights as to
what constrains or encourages cross-border collaboration.
However, this suggests that despite the efforts of trans-
national research networks (eg, Innovative Therapeutics for
Children with Cancer), current approaches to building and
sustaining these networks are not sufficient. This is an issue
for both regional funders, such as the European Union, and
domestic funding organizations in how they structure and
support international collaborations.
The 2 disease areas of cancer research that dominated
pediatric cancer were leukemia and CNS, reflecting the
prevalence of these disease groups. There was a wide
range in the types of research performed across most
disease types, with genetics, drug treatments, and prog-
nosis being the favored research domains. There was
a notable disease-specific predominance of some research
domains, which related to treatment pathway. For example,
CNS research was predominantly in radiotherapy and less
in other domains. Overall, across most disease areas, there
was less research in the fields of palliative and supportive
care, targeted therapy, and radiotherapy. There has been
a strong demand for more CNS research internationally,19
but our data support the need to increase the breadth of
pediatric cancer research to include other areas of unmet
clinical and research need.
Although the outputs of papers from the 3 world regions are
quite similar (Fig 1), the burden measured in DALYs20 from
pediatric cancers is much higher in the RoW than in Europe
or North America. This speaks to one of the most critical
and growing schisms in global pediatric cancer research,
namely, that between high-resource and middle-low–resource
settings. This is amajor failure that requires urgent reviewby the
leading research funders and overseas development funds.
Moreover, our finding about the hegemonic domination of
research by high-income countries is an issue that needs ur-
gent attention.
The number of times a paper has been cited reflects the
impact of research produced on other researchers.21 The
Netherlands, the United States, and the United Kingdom
are the countries with the most frequently cited papers. The
Netherlands spent only 3.2% of the world total in 2013, but
its papers were the most cited. Although this reflects well on
US, 729
DE, 94
JP, 93
CA, 80
UK, 65
IT, 59
AU, 53
FR, 49
NL, 49
Other EUR31, 176
Other RoW, 86
FIG 7. Distribution by country of the estimated world expenditure on
pediatric cancer research in 2013, in millions of US dollars, after
correction for calibration factor of × 1.09. AU, Australia; CA, Canada;
DE, Germany; EUR31, European Economic Area 31; FR, France; IT,
Italy; JP, Japan; NL, Netherlands; RoW, rest of the world; UK, United
Kingdom; US, United States.
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Dutch research, our analysis shows the need to increase
context-relevant research from low-middle–income coun-
tries with a growing burden from pediatric cancer.
Our study results are limited because we wanted to in-
clude as many papers as possible to gain a better un-
derstanding of global pediatric cancer research output,
but this introduced a potential error in papers included.
The precision of the pediatric cancer filter was 82%,
which means that nearly one-fifth of the papers may have
been included in error. However, as the recall was less
than this (0.75), the number of papers was actually
underestimated by approximately 9%. Finally, our esti-
mates of the expenditure on pediatric cancer research
depend on the assumption that the average cost of
a paper in this field is similar to that in other non-
communicable diseases research and that the cost does
not vary greatly by research domain or anatomic site. The
estimates also neglect those intramural expenditures by
companies that do not lead to publications in the open
literature,
As reflected in the WHO Global Childhood Cancer
Initiative,22 there is increasing recognition of the importance
of addressing the needs of childhood cancer, and research
is central to improving patient care and outcome. Our data
suggest there is a need internationally for greater in-
vestment in this field. Moreover, the current international
networks are being underused for cross-border collective
research. Collectively, the multidisciplinary stakeholders in
childhood cancer research would be well placed for co-
ordinated initiatives that ensure the full breadth of child-
hood cancer needs that are addressed in their respective
research programs.
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